Speakers - Sachs Associates

More documents

Recommendations

Info

<strong>Speakers</strong> Lorenza Castellón, Health & Biotech Equity Analyst, Equity Development Lorenza is a health & biotech equity analyst at Equity Development Ltd. covering private & publicly listed SMEs companies in Europe and Australia. Prior to joining Equity Development in January 2005 she held similar roles at leading international investment organisations. Equity Development brings together investors and companies by means of writing and distributing detailed research. We provide the markets with both facts and opinions along with fair valuations based upon diverse and appropriate metrics. Over the last decade our brand has become synonymous with quality objective research and we have built close links with institutions across the UK and Europe; like them we are fully regulated. Our team of analysts are FSA approved and boast a cumulative 400 years of experience. Please visit www.equitydevelopment.co.uk for more details and examples of our work or contact me. I am the health & biotech analyst and I have many years of experience in the sector having worked for leading international investment organisations. Ludo Haazen, Chief Medical Officer, PharmaNeuroBoost Ludo is Chief Medical Officer at PharmaNeuroBoost (PNB) since 2008. He has been directing Global Clinical Research, Development and Medical Affairs activities in different positions since 1995, mostly in CNS. As such, Ludo directed the Global Development of Durogesic® in chronic pain at JNJ, was involved in the development of antidepressants at Roche and JNJ, and assisted TiGenix in having ChondroCelect® approved as the first Advanced Therapy Medicinal Product (ATMP) in Europe. At PNB, Ludo has been instrumental in designing and directing the Phase I to III clinical development plans in Major Depression and Schizophrenia. He also is a registered Qualified Person for Pharmacovigilance. Lukas Guenther, Principal, Wellington Partners With an international background in clinical medicine and economics, Lukas joined the Wellington Life Science investment team in 2007. Prior to joining Wellington, Lukas had worked for six years as a surgeon and researcher specializing in organ and cell transplantation at the department of surgery at the Universities of Heidelberg and Freiburg. From 2000 to 2002, Lukas was a post-doctoral scientist at Harvard University in Boston, where he conducted research in the fields of immunology and protective genes. In 2003/2004 Lukas completed a fellowship in clinical islet transplantation at the University of Minnesota in Minneapolis, participating in NIH multicenter trials. Lukas studied Medical Sciences in Berlin and Cape Town. He holds a summa cum laude doctorate in Medicine from the Humboldt University Berlin and a Global OneMBA degree from RSM Erasmus University, Rotterdam. Malcolm Weir, Chief Executive Officer, Heptares Therapeutics Malcolm has a BSc and PhD in biochemistry and biophysics from Imperial College, London. He was Head of the Biomolecular Structure Department and then the Molecular Sciences Division of GlaxoWellcome with responsibility for 300 people engaged in target validation and lead discovery. During this time he led the application of structural biology and modelling to drug discovery, resulting in the advancement of clinical candidates to a wide range of diseases. He joined the structural bioinformatics and drug discovery company Inpharmatica Ltd as CEO in 2000, growing it from the spin-out stage to a 100-person company. Inpharmatica was sold to Galapagos NV in 2006. He joined MRC Technology in 2006 in order to establish Heptares Therapeutics Ltd in July 2007, as co-Founder and CEO. Malcolm was elected Visiting Professor of Biochemistry at Imperial College, London in 1997 and is on the Chemistry and Chemical Biology Advisory Boards at the same university. He served on the Council of the UK Biotechnology and Biological Sciences Research Council from 2004 – 2011. Marcel Tigges, CSO and Co-Founder, BioVersys AG Marcel is CSO and co-founder of BioVersys AG. He holds a M.Sc from Ludwig-Maximilians-University Munich and performed his PhD studies at ETH Zurich in the group of Prof. Martin Fussenegger. In 2009, he co-founded the BioVersys AG, a company performing research and development in the field of antimicrobial resistance. Since then, he is responsible for the implementation of synthetic biology derived assay modules into BioVersys`TRIC technology platform and the current development of BioVersys`LEAD molecules towards entering clinical phases. t back :: next u WELCOME PHARMA LICENSING GROUPS SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS
<strong>Speakers</strong> Marcel Zwaal, CBO, DCPrime After receiving his MSc in Finance and EMFC degree from VU University in Amsterdam, Marcel Zwaal (1967) has started his business career at Philips Electronics. Subsequently he has gained over 10 years of experience in international finance and controlling, both in a multinational setting and as an independent consultant. His experience in the field of vaccines and biotechnology started when joining Dutch biotech Crucell in 2006 where he has held several senior management positions in Business Development and Corporate Finance. He has been responsible for managing Crucell’s recombinant adeno vaccine development portfolio and he has concluded several collaborative financing and corporate restructuring deals. After the acquisition of Crucell by Johnson & Johnson, Mr. Zwaal has decided to join start-up company DCPrime as Chief Business Officer per Jan 1st, 2012. In this role he has been responsible for further developing the company strategy, professionalizing the organisation as well as rolling out the partnering and funding approach. Outside of his work he is a sport enthusiast and an avid rower and road racing cyclist. Markus Goebel, Partner, Novartis Venture Funds Markus is Managing Director, Novartis Venture Fund Markus Goebel started his career in the Health Care Industry in 1990. An MD by training and certified, amongst others, in hematology/oncology he worked for Farmitalia Germany and later held several global positions in R&D, Marketing and Strategy at Roche headquarters, partially in a ww alliance with Amgen. He joined Novartis in 2000 and first worked as global head Nervous System BD&L Pharma and later as global head Pharma Corporate M&A. In 2004 he joined the Novartis Venture Fund as a Managing Director in the US. Previously he received an MD and a PhD from the Ludwig Maximilian’s University in Munich and an MBA from Henley Management College. Markus serves on the boards of several Novartis Venture Fund portfolio companies, having exited, amongst others from Sirtris, FoldRx, EraGen and Intellikine. Markus Hosang, General Partner, BioMedPartners AG Markus is a General Partner at BioMedPartners AG in Basel, Switzerland. He has strong experience and broad knowledge in strategic and operational aspects of the venture capital business, as well as in pharmaceutical research and in many product development and marketing areas, with special expertise in the areas of biotechnologies, strategic alliances, and theranostics/diagnostics. Before joining BioMedPartners in 2004, Dr. Hosang was a Venture Partner at MPM Capital, where he was co-responsible for their European deal flow, and served on the boards of several European portfolio companies. Previously, he was at Roche in Basel, where, for nearly 20 years, he held several senior management positions in the Pharma R&D organization, including Vice President and Director of Global Pharma Research Strategic Unit and Chief of Staff to the President of Pharma R&D, membership of the Global Board of R&D Directors, Head of Development Projects in Basel and Member of the Roche Portfolio Board, and most recently, as a Deputy Head and Chief Scientific Officer of Genetics and Integrated Medicine, and a member of the Roche Genetics Executive Committee. He obtained his Ph.D. in Biochemistry from the ETH in Zurich and pursued his postgraduate training at Stanford University Medical School in neurobiology and subsequently at the University of Washington in Seattle in vascular dieseases. Dr. Hosang served on the Board of Directors and the Board of Trustees of the Swiss Foundation for Stipends in Medicine and Biology (SSMBS) as its Treasurer from 1994-2002. He currently is a member of the boards of Okairos AG, Suppremol GmbH and Anergis SA (as interim Chairman of the Board). Earlier he was on the boards of Omrix, Kourion (until its merger with ViaCell), IDEA, Atugen, Avontec and Neuraxo. He has published more than 30 articles in peer reviewed journals, and is coinventor on several patents. Martin Bonde, CEO, EpiTherapeutics ApS Martin is a serial entrepreneur, founded and managed several companies in Denmark and the US (Aros Pharma ApS, NatImmune A/S, Combio A/S, CelTor Inc., Torsana Biosensor, Osteometer Biotech) Martin fronted several successful exits over the last decade (NatImmune A/S to IPC, Combio A/S to Arpida AG, Torsana Biosensor A/S to Celtor Inc) as well as significant out-licensing deals, He is engaged as board member in Orphazyme ApS (www.orphazyme.com) (Chairman) and Danish Association of Biotech Companies (www.danskbiotek.dk) (Chairman). t back :: next u WELCOME PHARMA LICENSING GROUPS SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS
Page 1 and 2: B I O T E C H I N E U R O P E I N V
Page 3 and 4: Events Diary For regular updates, s
Page 5 and 6: Speakers Alexey Eliseev, Managing D
Page 7 and 8: Speakers Blake M. Paterson, Co-Foun
Page 9 and 10: Speakers David Slack, Head of Corpo
Page 11 and 12: Speakers Frank Grams, VP, Head Alli
Page 13 and 14: Speakers Iain Buchanan, CEO, NOXXON
Page 15: Speakers Juhani Lahdenperä, CEO, H
Page 19 and 20: Speakers Paul Higham, Managing Dire
Page 21 and 22: Speakers Richard Goodfellow, CEO, S
Page 23 and 24: Speakers Søren Moller, Managing In
Page 25 and 26: CONTACT Robert F Burns, PhD Chief E
Page 27 and 28: CONTACTS Rostislav Raykov Chief Exe
Page 29 and 30: CONTACTS Vincent Charlon PhD, CEO Z
Page 31 and 32: CONTACTS Dr Bassam Damaj Chairman,
Page 33 and 34: CONTACT Carina Schmidt Chief Execut
Page 35 and 36: CONTACT Mr Richard Godfrey Chief Ex
Page 37 and 38: CONTACTS Tom Kronbach, PhD Chief Ex
Page 39 and 40: CONTACTS Andreas Caduff, PhD Chief
Page 41 and 42: CONTACTS Dr Blake Paterson Co-Found
Page 43 and 44: CONTACT Wolfgang Kintzel Chief Exec
Page 45 and 46: CONTACT Mike Romanos PhD Chief Exec
Page 47 and 48: CONTACT Harry Welten, MBA Chief Fin
Page 49 and 50: CONTACT Barbara Stiefel Office Mana
Page 51 and 52: CONTACTS Ana Martinez Assistant Jua
Page 53 and 54: CONTACTS Dr Rudi D Neirinckx Chief
Page 55 and 56: CONTACT Martin Bonde, PhD, BComm Ch
Page 57 and 58: CONTACT Benedikt Timmerman Chief Ex
Page 59 and 60: CONTACT Malcolm Weir Chief Executiv
Page 61 and 62: CONTACTS Mr Paul Higham Chief Execu
Page 63 and 64: CONTACTS Kevin FitzGerald Chief Ope
Page 65 and 66: CONTACT Roel Q. J Schaapveld, PhD,
Page 67 and 68:
CONTACT Maaike Vogelezang Managemen
Page 69 and 70:
CONTACT Tom Johnston Chief Executiv
Page 71 and 72:
CONTACTS Aaron Powers President Dav
Page 73 and 74:
CONTACTS General and Media Contact
Page 75 and 76:
CONTACTS Martin Welschof Chief Exec
Page 77 and 78:
CONTACTS Carlos Buesa Chief Executi
Page 79 and 80:
CONTACTS Nick McCooke Chief Executi
Page 81 and 82:
CONTACT Dr Erik Buntinx Chief Execu
Page 83 and 84:
CONTACT Michael Altorfer, Ph.D. Hea
Page 85 and 86:
CONTACT Matthew B. Lehman Chief Ope
Page 87 and 88:
ADDRESS Otto-Hahn-Strasse 15 D- 442
Page 89 and 90:
CONTACT Dr Roman Schenk Chief Execu
Page 91 and 92:
CONTACTS Dr Hans Fliri Chairman Sim
Page 93 and 94:
CONTACTS Dr Raúl Insa Chief Execut
Page 95 and 96:
CONTACT Dr Johanna Holldack, MD Chi
Page 97 and 98:
CONTACT Eduardo Bravo (speaker) Man
Page 99 and 100:
CONTACTS Piers Morgan Chief Financi
Page 101 and 102:
CONTACT Jakob Knudsen Chief Executi
Page 103 and 104:
CONTACTS Dr Sonja Reingruber Chief
Page 105 and 106:
Supporting Organisations Citigate D
Page 107 and 108:
Supporting Organisations Life Scien
Page 109 and 110:
Supporting Organisations Swiss Biot
Page 111 and 112:
Supporting Organisations Torreya Pa
Page 113:
B I O T E C H I N E U R O P E I N V
show all

Speakers - Sachs Associates

Create successful ePaper yourself

Delete template?

Save as template?